Dignify Therapeutics is focused on developing innovative drug therapies aimed at restoring voluntary control over bowel and bladder functions for individuals suffering from neurological conditions or age-related issues. Their approach centers on creating "on-demand" medications that allow users to trigger bowel and bladder emptying at their convenience. This is particularly significant given the prevalence of incontinence and retention issues, which can lead to serious complications such as urinary tract infections and skin ulcerations. The company recognizes the stigma surrounding these conditions and aims to provide discreet, effective solutions that enhance quality of life.

The company is advancing two primary drug candidates: DTI-301 and DTI-117. DTI-301 is designed to induce on-demand defecation through a rectal suppository, leveraging a localized mechanism that minimizes systemic exposure while ensuring rapid action. DTI-117, on the other hand, offers dual functionality for both bowel and bladder control and can be administered as a sublingual film or via intramuscular injection. Both candidates are engineered to produce effects within minutes, allowing for quick and transient voiding, thereby reducing reliance on invasive treatments like catheters and manual bowel programs. Dignify Therapeutics aims to address significant unmet medical needs in this area, ultimately improving patient outcomes and reducing hospitalizations related to bowel and bladder dysfunction.

United States

Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal cord injured individuals.

Dignify Therapeutics

Company Details